Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-89495120 · 1 trial · 1 indication
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
| Arm | Type | Description |
|---|---|---|
| Arm 1: JNJ-89495120 Dose A | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
| Arm 2: JNJ-89495120 Dose A and Dose B | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
| Arm 3: Placebo Group | PLACEBO_COMPARATOR | Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
| Name | Type | Description |
|---|---|---|
| JNJ-89495120 | DRUG | JNJ-89495120 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: * Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MIN...
JNJ-89495120 is an investigational small molecule being studied for the treatment of Major Depressive Disorder. It is a Phase 2 investigational drug, meaning it has not been approved by regulatory authorities and is still in clinical development.
JNJ-89495120 is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research to evaluate the drug's efficacy in treating Major Depressive Disorder.
JNJ-89495120 is in Phase 2 of clinical development. It is an investigational drug, not yet approved by regulatory agencies. A Phase 2 study has been completed, which involved 107 participants with Major Depressive Disorder in the United States.
JNJ-89495120 has one completed clinical trial, registered as NCT06785012. This Phase 2 study explored the efficacy of JNJ-89495120 in treating Major Depressive Disorder. The trial was a randomized, double-blind, placebo-controlled study with 107 participants in the United States.
No, JNJ-89495120 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 2 trial (NCT06785012) evaluated its efficacy in Major Depressive Disorder, but the drug has not yet received regulatory approval for any use.